HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (vol 79, pg e45, 2018)

被引：0
|
作者：
Andreatta, K.
Chang, S.
Martin, R.
Acosta, R.
Daeumer, M.
Thielen, A.
Miller, M. D.
White, K. L.
机构：
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2018年 / 79卷 / 04期
关键词：
D O I：
10.1097/QAI.0000000000001892
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：E111 / E111
页数：1
相关论文
共 50 条
  • [11] Impact of archived M184V/I mutations on the effectiveness of switching to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide among virologically suppressed HIV-positive patients
    Chen, G-J
    Lee, Y-L
    Lee, C-H
    Cheng, C-Y
    Tang, H-J
    Tsai, H-C
    Huang, S-H
    Lee, Y-C
    Hsieh, M-H
    Chang, S-Y
    Su, L-S
    Chang, S-F
    Sun, H-Y
    Chuang, Y-C
    Hung, C-C
    HIV MEDICINE, 2019, 20 : 76 - 76
  • [12] Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
    Sax, Paul E.
    Wohl, David
    Yin, Michael T.
    Post, Frank
    DeJesus, Edwin
    Saag, Michael
    Pozniak, Anton
    Thompson, Melanie
    Podzamczer, Daniel
    Molina, Jean Michel
    Oka, Shinichi
    Koenig, Ellen
    Trottier, Benoit
    Andrade-Villanueva, Jaime
    Crofoot, Gordon
    Custodio, Joseph M.
    Plummer, Andrew
    Zhong, Lijie
    Cao, Huyen
    Martin, Hal
    Callebaut, Christian
    Cheng, Andrew K.
    Fordyce, Marshall W.
    McCallister, Scott
    LANCET, 2015, 385 (9987): : 2606 - 2615
  • [13] A randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat and emtricitabine (E/C/F) for initial HIV-1 treatment: week 96 results
    Clarke, A.
    Wohl, D.
    Oka, S.
    Clumeck, N.
    Brinson, C.
    Tashima, K.
    Arribas, J.
    Cheret, A.
    Brunetta, J.
    Sax, P.
    Zhong, L.
    Das, M.
    Fordyce, M.
    Elliott, C.
    HIV MEDICINE, 2016, 17 : 14 - 14
  • [14] Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials (vol 385, pg 2606, 2015)
    Sax, P. E.
    Wohl, D.
    Yin, M. T.
    LANCET, 2016, 387 (10030): : 1816 - 1816
  • [15] Phase IIIb, randomized, open-label study to evaluate switching from a tenofovir disoproxil fumarate (TDF)-containing regimen to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed, HIV-1 infected participants aged ≥60
    Maggiolo, F.
    Rizzardini, G.
    Raffi, F.
    Pulido, F.
    Mateo Garcia, G.
    Molina, J.
    Ong, E.
    Shao, Y.
    Corales, R.
    McNicholl, I.
    Piontkowsky, D.
    Das, M.
    Haubrich, R.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [16] Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients
    Huang, Yu-Shan
    Cheng, Chien-Yu
    Sun, Hsin-Yun
    Cheng, Shu-Hsing
    Lu, Po-Liang
    Lee, Chen-Hsiang
    Lee, Yuan-Ti
    Tsai, Hung-Chin
    Yang, Chia-Jui
    Liu, Chun-Eng
    Liou, Bo-Huang
    Lin, Shih-Ping
    Huang, Sung-Hsi
    Ho, Mao-Wang
    Tang, Hung-Jen
    Hung, Chien-Ching
    MICROBIOLOGY SPECTRUM, 2023, 11 (03):
  • [17] Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study
    Porter, Danielle P.
    Toma, Jonathan
    Tan, Yuping
    Solberg, Owen
    Cai, Suqin
    Kulkarni, Rima
    Andreatta, Kristen
    Lie, Yolanda
    Chuck, Susan K.
    Palella, Frank
    Miller, Michael D.
    White, Kirsten L.
    HIV CLINICAL TRIALS, 2016, 17 (01): : 29 - 37
  • [18] Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study
    Huhn, Gregory D.
    Eron, Joseph J.
    Girard, Pierre-Marie
    Orkin, Chloe
    Molina, Jean-Michel
    DeJesus, Edwin
    Petrovic, Romana
    Luo, Donghan
    Van Landuyt, Erika
    Lathouwers, Erkki
    Nettles, Richard E.
    Brown, Kimberley
    Wong, Eric Y.
    AIDS RESEARCH AND THERAPY, 2019, 16 (01)
  • [19] Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) versus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent
    Post, Frank
    Yazdanpanah, Yazdan
    Schembri, Gabriel
    Lazzarin, Adriano
    Reynes, Jacques
    Maggiolo, Franco
    Yan, Mingjin
    Abram, Michael
    Tran-Muchowski, Cecilia
    Cheng, Andrew
    Rhee, Martin
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [20] Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study
    Gregory D. Huhn
    Joseph J. Eron
    Pierre-Marie Girard
    Chloe Orkin
    Jean-Michel Molina
    Edwin DeJesus
    Romana Petrovic
    Donghan Luo
    Erika Van Landuyt
    Erkki Lathouwers
    Richard E. Nettles
    Kimberley Brown
    Eric Y. Wong
    AIDS Research and Therapy, 16
12345